

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER 52296AUSM1  U.S. APPLICATION NO. (If known, see 37 CFR 1.5) No Known
INTERNATIONAL APPLICATION NO. PCT/US03/11805	INTERNATIONAL FILING DATE 16 APRIL 2003 (16.04.2003)	PRIORITY DATE CLAIMED 19 APRIL 2002 (19.04.2002)
TITLE OF INVENTION NOVEL PROSTATE TUMOR-SPECIFIC PROMOTER		
APPLICANT(S) FOR DO/EO/US KRETSCHMER, Peter J. et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
<b>Items 11 to 20 below concern document(s) or information included:</b>		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A preliminary amendment. 14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Sequence Listing, Sequence Listing Identity Statement, Return Post Card		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JC20 Rec'd PCT/PTO 22 APR 2005

PTO-1390 (Rev. 07-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 2em; font-weight: bold;">10/532431</div>	INTERNATIONAL APPLICATION NO. PCT/US03/11805	ATTORNEY'S DOCKET NUMBER 52296AUSM1
--	---	--

  

21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1080.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....\$920.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$770.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....\$730.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....\$100.00 <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>	<b>CALCULATIONS</b> <b>PTO USE ONLY</b>
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	<div style="display: flex; justify-content: space-between;"> <span>\$ 100.00</span> <span></span> </div>

  

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	21 - 20 =	1	X \$18.00	\$ 18.00	
Independent claims	1 - 3 =	0	X \$86.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$290.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 118.00	

  

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

<b>SUBTOTAL =</b>	\$
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).	<div style="display: flex; justify-content: space-between;"> <span>\$</span> <span></span> </div>
<b>TOTAL NATIONAL FEE =</b>	\$ 118.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property	<div style="display: flex; justify-content: space-between;"> <span>\$</span> <span></span> </div>
<b>TOTAL FEES ENCLOSED =</b>	\$ 118.00

  

	Amount to be refunded: \$
	Amount to be charged: \$

  

a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 02-2117 in the amount of \$ 118.00 to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit  
 Account No. 02-2117. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not  
 be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed  
 and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Customer Number 27586

SIGNATURE

Wendy L. Washtien, Ph.D.

---

NAME

36,301

---

REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Kretschmer, Peter J. et al.	
Appln. No.:	Not yet known	
Filing Date:	Herewith	Examiner: Not yet known
Int'l App No.:	PCT/US03/11805	Group Art Unit: Not yet known
Int'l Filing Date:	April 16, 2003	
Title:	Novel Prostate Tumor-Specific Promoter	

**TRANSMITTAL OF SEQUENCE LISTING**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

ATTN: US/RO

Dear Sir:

Applicants hereby submit a Sequence Listing and a Sequence Listing in computer readable form (as required under 37 CFR § 1.821-1.825).

Applicants' attorney attests that the information recorded in computer readable form is identical to the written sequence listing, as required under 37 CFR § 1.821(f). This submission introduces no new matter, since the enclosed sequences are identical to the sequences which were submitted in the original patent application, International Application No. PCT/US03/11805.

Respectfully submitted,

BERLEX INC.  
Customer Number 27586

Wendy L. Washtien  
Wendy L. Washtien, Ph.D., Reg. No. 36,301  
Patent Agent

Date: April 22, 2005

Corporate Patents  
2600 Hilltop Drive  
Richmond, California 94806  
(510) 262-5000